Business Context and Reporting Period
Company: Boston Scientific Corporation (BSX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A global developer, manufacturer, and marketer of medical devices organized into two reportable segments: MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (Interventional Cardiology & Vascular Therapies, Watchman, Electrophysiology, Cardiac Rhythm Management, Interventional Oncology & Embolization). The company operates in 127 countries with approximately 59,000 employees.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $20,074 | $16,747 | +19.9% |
| Gross Profit | $13,854 | $11,490 | +20.6% |
| Gross Margin | 69.0% | 68.6% | +40 bps |
| Operating Income | $3,613 | $2,603 | +38.8% |
| Net Income (GAAP) | $2,898 | $1,853 | +56.4% |
| Adjusted Net Income (Non-GAAP) | $4,574 | $3,725 | +22.8% |
| Diluted EPS (GAAP) | $1.94 | $1.25 | +55.2% |
| Diluted EPS (Adjusted) | $3.06 | $2.51 | +21.9% |
| Operating Cash Flow | $4,534 | $3,435 | +31.9% |
| Total Debt | $11,436 | $10,746 | +6.4% |
| Cash & Equivalents | $1,965 | $414 | +374.6% |
Liquidity: As of December 31, 2025, the company held $1.965 billion in unrestricted cash and cash equivalents and had $2.750 billion available under its revolving credit facility. The company is in compliance with its financial covenants, with a leverage ratio of 1.92x against a maximum permitted ratio of 4.50x.
Material Changes vs. Prior Period
- Revenue Growth: Reported net sales grew 19.9% to $20.074 billion, driven by operational growth of 19.2% and organic growth of 15.8%. The Cardiovascular segment saw the strongest growth at 23.2%, led by the Electrophysiology business unit (Farapulse PFA System) and Watchman devices. MedSurg grew 13.9%.
- Profitability: Operating income increased significantly due to revenue growth and margin expansion. Gross margin improved to 69.0%, aided by higher sales of higher-margin products, partially offset by inventory charges related to the discontinuation of the ACURATE platform and increased tariffs.
- Acquisitions: In 2025, the company completed acquisitions of Bolt Medical, SoniVie, Intera Oncology, Cortex, and Anrei Medical. These contributed to the "Impact of certain acquisitions" line item in growth calculations.
- Restructuring: The company expanded its 2023 Restructuring Plan, incurring total pre-tax charges of approximately $668 million through year-end 2025. This included $101 million in restructuring net charges and $242 million in restructuring-related net charges.
- Discontinuations: The company discontinued worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, resulting in approximately $87 million in pre-tax charges.
Guidance, Outlook, Risks, and Unusual Items
- Major Acquisition: On January 15, 2026, the company announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion ($374 per share). The transaction is expected to close in 2026 and will be funded by cash on hand, new debt (~$11 billion), and common stock.
- Recent Acquisition: On January 27, 2026, the company completed the acquisition of Nalu Medical, Inc. for approximately $517 million (net of cash).
- Regulatory Environment: The company continues to incur costs related to EU Medical Device Regulation (MDR) implementation, with cumulative expenses of $464 million through 2025. Total expected costs are $475 million to $525 million.
- Tax Matters: The reported tax rate was 14.6% in 2025, lower than the 19.1% in 2024, due to acquisition-related charges and discrete tax benefits. The company is monitoring the implementation of the OECD Pillar Two global minimum tax framework.
- Risks: Key risks include intense competition, pricing pressure from government tenders and consolidation, supply chain disruptions, cybersecurity threats, and the outcome of ongoing litigation (including product liability and intellectual property disputes).
- Unusual Items: The company recorded $194 million in litigation-related net charges in 2025 related to the resolution of a legacy IP matter. It also recorded a $205 million gain on investments related to the remeasurement of its Bolt Medical stake.
Investor Verification Checklist
- Penumbra Acquisition: Verify the closing conditions, regulatory approval status, and integration plan for the $14.5 billion Penumbra acquisition announced in January 2026.
- Debt Capacity: Assess the impact of the planned $11 billion debt issuance for the Penumbra deal on the company's leverage ratio and credit rating, given the current 1.92x leverage.
- Product Discontinuation: Review the long-term impact of discontinuing the ACURATE aortic valve platform on the Cardiovascular segment's revenue and market share.
- EU MDR Costs: Monitor the remaining EU MDR implementation costs and their effect on future operating margins.
- Litigation Exposure: Evaluate the status of ongoing product liability litigation (specifically transvaginal surgical mesh) and intellectual property disputes, noting the $242 million legal accrual as of year-end 2025.
- Organic Growth Sustainability: Analyze the sustainability of the 15.8% organic growth rate, particularly the contribution from the Farapulse PFA System in Electrophysiology.